Alx Oncology Holdings (ALXO) Asset Writedowns and Impairment (2025)

Alx Oncology Holdings (ALXO) reported Asset Writedowns and Impairment of $25000.0 for Q4 2025, down 99.22% sequentially from $3.2 million in Q2 2025.

Alx Oncology Holdings (ALXO) Asset Writedowns and Impairment (2025) Analysis & Trends

Alx Oncology Holdings (ALXO) has 1 years of Asset Writedowns and Impairment data on file, last reported at $25000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Alx Oncology Holdings	211.40 Mn	211.40 Mn	-

Download Data